医学
肠促胰岛素
利拉鲁肽
减肥
超重
中止
2型糖尿病
艾塞那肽
内科学
胰高血糖素样肽1受体
糖尿病
药理学
肥胖
内分泌学
兴奋剂
受体
作者
Ashwin K. Chetty,Ebne Rafi,Natalie Bellini,Natalie Buchholz,Diana Isaacs
标识
DOI:10.1016/j.eprac.2023.12.010
摘要
To review clinical trial data for incretin therapies that are approved or in late-stage development for overweight or obesity management, along with clinical implications of these therapies and future directions.
科研通智能强力驱动
Strongly Powered by AbleSci AI